Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
At Cymbiotika, we believe that understanding the science behind what you put into your body is the first step toward lasting wellness
These approaches have led to significant weight loss with the dual GLP-1/glucagon receptor agonist survodutide (-13.5% with the 6-mg dose at 76 weeks in a phase 3 SYNCHRONIZE-1 trial) [16] , the dual GLP-1 receptor agonist and GIP antagonist Maridebart cafraglutide (known as MariTide) (-12.3% to -16.2% across different doses at 52 weeks in a phase 2 trial) [17] or the triple GLP-1/GIP/glucagon receptor agonist retatrutide (-24.2% with the 12-mg dose at 48 weeks in a phase 2 trial) [18]
Over time, laboratory studies began to investigate its theoretical benefits on musculoskeletal and neural tissues
General precautions: Retatrutide should be used only under medical supervision
Ambruso, S
Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases
